IL-33 activates tumor stroma to promote intestinal polyposis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 19, 2015, Pages E2487-E2496

  Maywald, Rebecca L ^a   Doerner, Stephanie K ^b   Pastorelli, Luca ^b,c,d   De Salvo, Carlo ^b   Benton, Susan M ^a   Dawson, Emily P ^a   Lanza, Denise G ^a   Berger, Nathan A ^b   Markowitz, Sanford D ^b,e   Lenz, Heinz Josef ^f   Nadeau, Joseph H ^g   Pizarro, Theresa T ^b   Heaney, Jason D ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MILAN   (Italy)

^d IRCCS POLICLINICO SAN DONATO   (Italy)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

Author keywords

ApcMin; Colorectal cancer; IL 33; Th2 immunity; Wound healing

Indexed keywords

ANTIBODY; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR TYPE 4; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 33; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; IL33 PROTEIN, HUMAN; IL33 PROTEIN, MOUSE; INTERLEUKIN DERIVATIVE; TRANSCRIPTOME;

ADENOMATOUS POLYP; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL ACTIVATION; CELL PROLIFERATION; COLON ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; GASTROINTESTINAL POLYPOSIS; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MAST CELL; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; C57BL MOUSE; COLON POLYP; COLON TUMOR; COLORECTAL TUMOR; DNA MICROARRAY; EPITHELIUM CELL; GENE EXPRESSION REGULATION; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); SIGNAL TRANSDUCTION; TH2 CELL; TRANSGENIC MOUSE; WOUND HEALING;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; COLONIC NEOPLASMS; COLONIC POLYPS; COLORECTAL NEOPLASMS; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-33; INTERLEUKINS; INTESTINAL POLYPOSIS; MAST CELLS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOFIBROBLASTS; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TH2 CELLS; TRANSCRIPTOME; WOUND HEALING;

EID: 84929191609     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1422445112     Document Type: Article

References (80)

1. Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal cancer. Cell 87(2): 159-170.
2. Powell SM, et al. (1992) APC mutations occur early during colorectal tumorigenesis. Nature 359(6392):235-237.
3. Fodde R, Smits R, Clevers H (2001) APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 1(1):55-67.
4. Terzić J, Grivennikov S, Karin E, Karin M (2010) Inflammation and colon cancer. Gastroenterology 138(6):2101-2114, e5.
5. Powell DW, Adegboyega PA, Di Mari JF, Mifflin RC (2005) Epithelial cells and their neighbors I. Role of intestinal myofibroblasts in development, repair, and cancer. Am J Physiol Gastrointest Liver Physiol 289(1):G2-G7.
6. Gause WC, Wynn TA, Allen JE (2013) Type 2 immunity and wound healing: Evolutionary refinement of adaptive immunity by helminths. Nat Rev Immunol 13(8): 607-614.
7. Owens BM, Simmons A (2013) Intestinal stromal cells in mucosal immunity and homeostasis. Mucosal Immunol 6(2):224-234.
8. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144(5):646-674.
9. Bhowmick NA, Neilson EG, Moses HL (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432(7015):332-337.
10. Elenbaas B, Weinberg RA (2001) Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res 264(1):169-184.
11. Calon A, et al. (2012) Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell 22(5):571-584.
12. Tsushima H, et al. (2001) Circulating transforming growth factor beta 1 as a predictor of liver metastasis after resection in colorectal cancer. Clin Cancer Res 7(5):1258-1262.
13. Lopetuso LR, Scaldaferri F, Pizarro TT (2012) Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis. Fibrogenesis Tissue Repair 5(1):18.
14. Wood IS, Wang B, Trayhurn P (2009) IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem Biophys Res Commun 384(1):105-109.
15. Moussion C, Ortega N, Girard JP (2008) The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: A novel 'alarmin'? PLoS ONE 3(10):e3331.
16. Schmitz J, et al. (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23(5):479-490.
17. Carriere V, et al. (2007) IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA 104(1):282-287.
18. Saenz SA, Taylor BC, Artis D (2008) Welcome to the neighborhood: Epithelial cellderived cytokines license innate and adaptive immune responses at mucosal sites. Immunol Rev 226:172-190.
19. Lüthi AU, et al. (2009) Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 31(1):84-98.
20. Chackerian AA, et al. (2007) IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 179(4):2551-2555.
21. Hayakawa H, Hayakawa M, Kume A, Tominaga S (2007) Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 282(36):26369-26380.
22. Lopetuso LR, Chowdhry S, Pizarro TT (2013) Opposing functions of classic and novel IL-1 family members in gut health and disease. Front Immunol 4:181.
23. Humphreys NE, Xu D, Hepworth MR, Liew FY, Grencis RK (2008) IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol 180(4):2443-2449.
24. Beltrán CJ, et al. (2010) Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis 16(7):1097-1107.
25. Kobori A, et al. (2010) Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol 45(10):999-1007.
26. Pastorelli L, et al. (2010) Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci USA 107(17):8017-8022.
27. Seidelin JB, et al. (2010) IL-33 is upregulated in colonocytes of ulcerative colitis. Immunol Lett 128(1):80-85.
28. Sponheim J, et al. (2010) Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am J Pathol 177(6): 2804-2815.
29. Cui G, et al. (2015) Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer. Cancer Immunol Immunother 64(2): 181-190.
30. Liu X, et al. (2014) IL-33/ST2 pathway contributes to metastasis of human colorectal cancer. Biochem Biophys Res Commun 453(3):486-492.
31. Skrzypczak M, et al. (2010) Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PLoS ONE 5(10).
32. Sabates-Bellver J, et al. (2007) Transcriptome profile of human colorectal adenomas. Mol Cancer Res 5(12):1263-1275.
33. Taketo MM, Edelmann W (2009) Mouse models of colon cancer. Gastroenterology 136(3):780-798.
34. Palmer G, et al. (2009) Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum 60(3):738-749.
35. Karin M (2009) NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 1(5):a000141.
36. Choi YS, et al. (2009) Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood 114(14): 3117-3126.
37. Powell DW, et al. (1999) Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Am J Physiol 277(2 Pt 1):C183-C201.
38. Nishida A, et al. (2010) Expression of interleukin 1-like cytokine interleukin 33 and its receptor complex (ST2L and IL1RAcP) in human pancreatic myofibroblasts. Gut 59(4): 531-541.
39. Andoh A, Bamba S, Brittan M, Fujiyama Y, Wright NA (2007) Role of intestinal subepithelial myofibroblasts in inflammation and regenerative response in the gut. Pharmacol Ther 114(1):94-106.
40. Andoh A, Bamba S, Fujiyama Y, Brittan M, Wright NA (2005) Colonic subepithelial myofibroblasts in mucosal inflammation and repair: Contribution of bone marrow-derived stem cells to the gut regenerative response. J Gastroenterol 40(12):1089-1099.
41. Andoh A, Fujino S, Okuno T, Fujiyama Y, Bamba T (2002) Intestinal subepithelial myofibroblasts in inflammatory bowel diseases. J Gastroenterol 37(Suppl 14):33-37.
42. Hinterleitner TA, Saada JI, Berschneider HM, Powell DW, Valentich JD (1996) IL-1 stimulates intestinal myofibroblast COX gene expression and augments activation of Cl-secretion in T84 cells. Am J Physiol 271(4 Pt 1):C1262-C1268.
43. Zucker S, Vacirca J (2004) Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 23(1-2):101-117.
44. Mukaratirwa S, de Witte E, van Ederen AM, Nederbragt H (2003) Tenascin expression in relation to stromal tumour cells in canine gastrointestinal epithelial tumours. J Comp Pathol 129(2-3):137-146.
45. Lunderius-Andersson C, Enoksson M, Nilsson G (2012) Mast cells respond to cell injury through the recognition of IL-33. Front Immunol 3:82.
46. Enoksson M, et al. (2011) Mast cells as sensors of cell injury through IL-33 recognition. J Immunol 186(4):2523-2528.
47. Gounaris E, et al. (2007) Mast cells are an essential hematopoietic component for polyp development. Proc Natl Acad Sci USA 104(50):19977-19982.
48. Blatner NR, et al. (2010) In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proc Natl Acad Sci USA 107(14):6430-6435.
49. Cheon EC, et al. (2011) Mast cell 5-lipoxygenase activity promotes intestinal polyposis in APCDelta468 mice. Cancer Res 71(5):1627-1636.
50. Gurish MF, Boyce JA (2006) Mast cells: Ontogeny, homing, and recruitment of a unique innate effector cell. J Allergy Clin Immunol 117(6):1285-1291.
51. Friend DS, et al. (1996) Mast cells that reside at different locations in the jejunum of mice infected with Trichinella spiralis exhibit sequential changes in their granule ultrastructure and chymase phenotype. J Cell Biol 135(1):279-290.
52. Dalgleish AG, O'Byrne KJ (2002) Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer. Adv Cancer Res 84:231-276.
53. Kidd P (2003) Th1/Th2 balance: The hypothesis, its limitations, and implications for health and disease. Altern Med Rev 8(3):223-246.
54. Terabe M, Park JM, Berzofsky JA (2004) Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol Immunother 53(2):79-85.
55. Romagnani S (1997) The Th1/Th2 paradigm. Immunol Today 18(6):263-266.
56. Arwert EN, Hoste E, Watt FM (2012) Epithelial stem cells, wound healing and cancer. Nat Rev Cancer 12(3):170-180.
57. O'Hara RJ, et al. (1998) Advanced colorectal cancer is associated with impaired interleukin 12 and enhanced interleukin 10 production. Clin Cancer Res 4(8):1943-1948.
58. Pellegrini P, et al. (1996) Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 42(1):1-8.
59. Shibata M, et al. (2002) Decreased production of interleukin-12 and type 2 immune responses are marked in cachectic patients with colorectal and gastric cancer. J Clin Gastroenterol 34(4):416-420.
60. Kurzrock R (2001) Cytokine deregulation in cancer. Biomed Pharmacother 55(9-10): 543-547.
61. Nakanishi Y, et al. (2011) COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps. Carcinogenesis 32(9): 1333-1339.
62. Kojima M, et al. (2001) Association of enhanced cyclooxygenase-2 expression with possible local immunosuppression in human colorectal carcinomas. Ann Surg Oncol 8(5):458-465.
63. Kalinski P (2012) Regulation of immune responses by prostaglandin E2. J Immunol 188(1):21-28.
64. Yanagawa Y, Suzuki M, Matsumoto M, Togashi H (2011) Prostaglandin E(2) enhances IL-33 production by dendritic cells. Immunol Lett 141(1):55-60.
65. Jovanovic I, et al. (2011) ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma. Eur J Immunol 41(7):1902-1912.
66. Jovanovic IP, et al. (2014) Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer 134(7):1669-1682.
67. Chen SF, et al. (2013) The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol 231(2):180-189.
68. Schmieder A, Multhoff G, Radons J (2012) Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells. Cytokine 60(2):514-521.
69. Li J, et al. (2014) Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest 124(7):3241-3251.
70. Herbst A, et al. (2014) Comprehensive analysis of β-catenin target genes in colorectal carcinoma cell lines with deregulated Wnt/β-catenin signaling. BMC Genomics 15:74.
71. Carmeliet P (2005) VEGF as a key mediator of angiogenesis in cancer. Oncology 69 (Suppl 3):4-10.
72. Waugh DJ, Wilson C (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14(21):6735-6741.
73. Voehringer D (2013) Protective and pathological roles of mast cells and basophils. Nat Rev Immunol 13(5):362-375.
74. Abraham SN, St John AL (2010) Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 10(6):440-452.
75. Bischoff SC (2009) Physiological and pathophysiological functions of intestinal mast cells. Semin Immunopathol 31(2):185-205.
76. Maltby S, Khazaie K, McNagny KM (2009) Mast cells in tumor growth: Angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta 1796(1):19-26.
77. Wedemeyer J, Galli SJ (2005) Decreased susceptibility of mast cell-deficient Kit(W)/Kit (W-v) mice to the development of 1, 2-dimethylhydrazine-induced intestinal tumors. Lab Invest 85(3):388-396.
78. Groschwitz KR, Wu D, Osterfeld H, Ahrens R, Hogan SP (2013) Chymase-mediated intestinal epithelial permeability is regulated by a protease-activating receptor/matrix metalloproteinase-2-dependent mechanism. Am J Physiol Gastrointest Liver Physiol 304(5):G479-G489.
79. Sjöblom T, et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314(5797):268-274.
80. Carmona-Saez P, Chagoyen M, Tirado F, Carazo JM, Pascual-Montano A (2007) GENECODIS: A web-based tool for finding significant concurrent annotations in gene lists. Genome Biol 8(1):R3.